Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209111) titled 'A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014)' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Merck Sharp & Dohme LLC
Condition:
Neoplasm Malignant
Intervention:
Drug: MK-1084
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 24, 2025
Target Sample Size: 150
To know more, visit https://clinicaltrials.gov/study/NCT07209111
Published by HT Digital Content Services with permission from Health Da...